BRCA1-and BRCA2-related mutations: Therapeutic implications in ovarian cancer

Annals of Oncology

Volumn 24, Issue SUPPL.B, 2013, Pages

  Pothuri, B ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1 BRCA2; BRCAness ovarian cancer; PARP inhibitors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CEP 9722; DOXORUBICIN; INIPARIB; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PACLITAXEL; PLACEBO; RAD51 PROTEIN; RUCAPARIB; TEMOZOLOMIDE; VELIPARIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; DNA REPAIR; DRUG DOSE ESCALATION; DRUG MECHANISM; EXCISION REPAIR; FAMILIAL CANCER; GENE FUNCTION; GENE MUTATION; GENOME; HOMOLOGOUS RECOMBINATION; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

BRCA1/BRCA2; BRCANESS OVARIAN CANCER; PARP INHIBITORS;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA REPAIR; FEMALE; HETEROZYGOTE; HOMOLOGOUS RECOMBINATION; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84886296822     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt307     Document Type: Article

References (76)

1. Cancer Facts & Figures 2009, A.C. Society, Editor. 2009: Atlanta, GA.
2. Covens A, Carey M, Bryson P et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002; 85(1): 71-80.
3. Gadducci A, Sartori E, Maggino T et al. Analysis of failures after negative secondlook in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol 1998; 68: 150-155.
4. Madigan MP, Ziegler RG, Benichou J et al. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995; 87(22): 1681-1685.
5. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266(5182): 66-71.
6. Wooster R, Bignell G, Lancester J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378(6559): 789-792.
7. Brose MS, Rebbeck TR, Calzone KA et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94(18): 1365-1372.
8. Thompson D, D.F. Easton, and C. the Breast Cancer Linkage, Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94(18): 1358-1365.
9. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348(23): 2339-2347.
10. Risch HA, McLaughlin JR, Cole DEC et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68(3): 700-710.
11. Malander S, Ridderheim M, Masback A et al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer 2004; 40(3): 422-428.
12. Menkiszak J, Gronwald J, Gorski B et al. Hereditary ovarian cancer in Poland. Int J Cancer 2003; 106(6): 942-945.
13. Pal T, Permuth-Wey J, Betts JA et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104(12): 2807-2816.
14. Parikh RA, White JS, Huang X et al. Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma. Genes Chromosomes Cancer 2007; 46: 761-775.
15. Meijers-Heijboer H, van den Ouwelan A, Klijn J et al. Low-penetrance susceptibility to breast cancer due to CHEK2()1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-59.
16. Liu Y, West S. Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res 2002; 4(1): 9-13.
17. Suzuki A, de la Pompa JK, Hakem R et al. BRCA2 Is required for embryonic cellular proliferation in the mouse. Genes Dev 1997; 11: 1242-1252.
18. Hohenstein P, Kleiman MF, Breukel C et al. A targeted mouse BRCA1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene 2001; 20: 2544-2550.
19. Yu VP, Koehler M, Steinlein C et al. Gross chromosomal rearrangements and genetic exchange between non-homologous chromosomes following BRCA2 inactivation. Genes Dev 2000; 14: 1400-1406.
20. Xu X, Weaver Z, Linke SP et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999; 3(3): 389-395.
21. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108(2): 171-182.
22. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001; 27: 247-254.
23. Moynahan ME, Chiu JW, Koller BH et al. Brca1 controls homology-directed DNA repair. Mol Cell 1999; 4(4): 511-518.
24. Moynahan ME, Pierce AJ, Jasin M. BRCA2 Is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7(2): 263-272.
25. Tutt A, Bertwistle D, Valentine J et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001; 20(17): 4704-4716.
26. Wang Y, Cortez D, Yazdi P et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000; 14: 927-939.
27. Paull TT, Rogakou EP, Yamazaki V et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000; 10(15): 886-895.
28. Bochar DA, Wang L, Beniya H et al. BRCA1 Is associated with a human SWI/SNFrelated complex: linking chromatin remodeling to breast cancer. Cell 2000; 102 (2): 257-265.
29. Ye Q, Hu YF, Zhong H et al. BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations. J Cell Biol 2001; 155(6): 911-922.
30. Ruffner H, Joazeiro CA, Hemmati D et al. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 2001; 98(9): 5134-5139.
31. Wong AK, Pero R, Ormonde PA et al. RAD51 Interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997; 272(51): 31941-31944.
32. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283(17): 2260-2265.
33. Chetrit A, Hirsh-Yechezkel G, Ben-David Y et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008; 26(1): 20-25.
34. Tan DS, Rothermundt C, Thomas K et al. 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26(34): 5530-5536. Epub 2008 Oct 27.
35. Cass I, Baldwin RL, Varkey T et al. Improved survival in women with BRCAassociated ovarian carcinoma. Cancer 2003; 97: 2187-2195.
36. Yang D, Khan S, Sun Y et al. Association of BRCA1 and BRCA2 mutations with survival, chemo- therapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306: 1557-1565.
37. Amé J-C, Spenlehauer C, Murcia Gd. The PARP superfamily. Bioessays 2004; 26(8): 882-893.
38. de Murcia G, de Murcia JM. Poly(ADP-ribose) polymerase: a molecular nicksensor. Trends Biochem Sci 1994; 19(4): 172-176.
39. D'Amours D, Desnoyers S, D'Silva I et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999; 342(2): 249-268.
40. Poirier GG, de Murcia G, Jongstra-Bilen J et al. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc Natl Acad Sci USA 1982; 79(11): 3423-3427.
41. Okano S, Lan L, Caldecott KW et al. Spatial and temporal cellular responses to single-strand breaks in human cells. Mol Cell Biol 2003; 23(11): 3974-3981.
42. Caldecott KW. XRCC1 and DNA strand break repair. DNA Repair 2003; 2(9): 955-969.
43. Hoeijakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411(6835): 366-374.
44. Dantzer F, Schreiber V, Niedergang C et al. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 1999; 81(1-2): 69-75.
45. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917-921.
46. Dantzer F, de La Rubia G, Méissier-De Murcia J et al. Base excision repair Is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1â. Biochemistry 2000; 39(25): 7559-7569.
47. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434(7035): 913-917.
48. Schultz N, Lopez E, Saleh-Gohari N et al. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 2003; 31: 4959-4964.
49. Yang YG, Cortes U, Patnaik S et al. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 2004; 23: 3872-3882.
50. Wielckens K, Garbrecht M, Kittler M et al. ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells. Eur J Biochem 1980; 104(1): 279-287.
51. Hirai K, Ueda K, Hayaishi O. Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. Cancer Res 1983; 43(7): 3441-3446.
52. Tomoda T, Kurashige T, Moriki T et al. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 1991; 37(4): 223-227.
53. Shiobara M, Miyazaki M, Ito H et al. Enhanced polyadenosinediphosphateribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001; 16(3): 338-344.
54. D'Atri S, Tenori L, Lacal PM et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998; 54(2): 334-341.
55. Plummer ER, Middleton MR, Jones C et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005; 11(9): 3402-3409.
56. Curtin NJ, Wang LZ, Yiakouvaki A et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repairdeficient cells. Clin Cancer Res 2004; 10(3): 881-889.
57. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361(2): 123-134. Epub 2009 Jun 24.
58. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-2519.
59. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
60. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet 2011; 12: 852-861.
61. Ledermann JA, Harter P, Gourley C et al. Phase II randomized placebocontrolled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol 2011; 29(suppl): abstract 5003.
62. Kaye S, Kaufman B, Lubinski J et al. Phase II study of the oral PARP inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations. European Society for Medical Oncology (ESMO) Congress. 2010; Oct 8-12, 2010. Milan, Italy. Abstract 3725.
63. Ji JJ, Kummar S, Chen AP et al. Pharmacodynamic response in phaseI combination study of ABT-888 and topotecan in adults with refractory solid tumors andlymphomas. J ClinOncol 2010; 28(suppl 15s): abstract 2514.
64. Lorusso P, Ji JJ, Li J et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. J Clin Oncol 2011; 29(suppl): abstract 3000.
65. Yang HJ, Liu VWS, Wang Y et al. Differential DNA methylation profiles in gynaecological cancers and correlation with clinico-pathological data. BMC Cancer 2006; 6: 212.
66. Press JZ, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17-24.
67. Taniguchi T, Tischkowitz M, Ameziane N et al. Disruption of the Fanconi anemia- BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9(5): 568-574.
68. Hughes-Davies L, Huntsman D, Ruas M et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115(5): 523-535.
69. Brown LA, Irving J, Parker R et al. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 2006; 100: 264-270.
70. Hughes-Davies L, Huntsman D, Ruas M et al. EMSY Links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115: 523-535.
71. Cousineau I, Belmaaza A. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/ recombination syndromes as checkpoint diseases. Mol Genet Genomics 2011; 285: 325-340.
72. D'Andrea AD. The Fanconi anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003; 2: 290-292.
73. Shen WH, Balajee AS, Wang J et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128: 157-170.
74. Walsh T, Lee MK, Casadei S et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. PNAS 2010; 107: 12629-12633.
75. Walsh T, Casadei S, Lee M et al. Mutations in 12 genes for inherited ovarian, fallopian tune, and peritoneal carcinoma identified by massive parallel sequencing. PNAS 2011; 108: 18032-18037.
76. Bell D, Berchuck A, Birrer M et al. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.